Key publications of the last five years

2024

Mayer KA, Schrezenmeier E, Diebold M, et al. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. N Engl J Med. Published online May 25, 2024. doi:10.1056/NEJMoa2400763

Diebold M, Farkash EA, Barnes J, et al. Natural Killer Cell Presence in Antibody-Mediated Rejection. Transpl Int. 2024;37:13209. Published 2024 Jun 24. doi:10.3389/ti.2024.13209     

Diebold M, Vietzen H, Heinzel A, et al. Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation. Am J Transplant. 2024;24(5):743-754. doi:10.1016/j.ajt.2023.12.005

Regele F, Haupenthal F, Doberer K, et al. The kinetics of Torque Teno virus plasma load following calcineurin inhibitor dose change in kidney transplant recipients. J Med Virol. 2024;96(3):e29554. doi:10.1002/jmv.29554

2023

Herz CT, Diebold M, Kainz A, et al. Morphologic and Molecular Features of Antibody-Mediated Transplant Rejection: Pivotal Role of Molecular Injury as an Independent Predictor of Renal Allograft Functional Decline. Transpl Int. 2023;36:12135. Published 2023 Dec 19. doi:10.3389/ti.2023.12135

Haupenthal F, Rahn J, Maggi F, et al. A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT. Trials. 2023;24(1):213. Published 2023 Mar 22. doi:10.1186/s13063-023-07216-0

Böhmig GA, Halloran PF, Feucht HE. On a Long and Winding Road: Alloantibodies in Organ Transplantation. Transplantation. 2023;107(5):1027-1041. doi:10.1097/TP.0000000000004550

Görzer I, Haupenthal F, Maggi F, et al. Validation of plasma Torque Teno viral load applying a CE-certified PCR for risk stratification of rejection and infection post kidney transplantation. J Clin Virol. 2023;158:105348. doi:10.1016/j.jcv.2022.105348

Borski A, Eskandary F, Haindl S, et al. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena. Transplantation. 2023;107(2):495-503. doi:10.1097/TP.0000000000004285

2022

Mayer KA, Budde K, Jilma B, Doberer K, Böhmig GA. Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials. Expert Opin Emerg Drugs. 2022;27(2):151-167. doi:10.1080/14728214.2022.2091131

Vietzen H, Döhler B, Tran TH, et al. Deletion of the Natural Killer Cell Receptor NKG2C Encoding KLR2C Gene and Kidney Transplant Outcome. Front Immunol. 2022;13:829228. Published 2022 Mar 24. doi:10.3389/fimmu.2022.829228

Mayer KA, Budde K, Halloran PF, et al. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Trials. 2022;23(1):270. Published 2022 Apr 8. doi:10.1186/s13063-022-06198-9

2021

Mayer KA, Doberer K, Tillgren A, et al. Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients. Transpl Int. 2021;34(9):1689-1702. doi:10.1111/tri.13970

Doberer K, Duerr M, Halloran PF, et al. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2021;32(3):708-722. doi:10.1681/ASN.2020071106

Doberer K, Kläger J, Gualdoni GA, et al. CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. Transplantation. 2021;105(2):451-457. doi:10.1097/TP.0000000000003247

2020

Viklicky O, Krivanec S, Vavrinova H, et al. Crossing borders to facilitate live donor kidney transplantation: the Czech-Austrian kidney paired donation program - a retrospective study. Transpl Int. 2020;33(10):1199-1210. doi:10.1111/tri.13668

Mühlbacher J, Doberer K, Kozakowski N, et al. Non-invasive Chemokine Detection: Improved Prediction of Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Renal Allograft Recipients. Front Med (Lausanne). 2020;7:114. Published 2020 Apr 9. doi:10.3389/fmed.2020.00114

Doberer K, Schiemann M, Strassl R, et al. Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients-A prospective observational trial. Am J Transplant. 2020;20(8):2081-2090. doi:10.1111/ajt.15810

Doberer K, Bond G, Kläger J, et al. Immunoadsorption Combined with Membrane Filtration to Counteract Early Treatment-Refractory Antibody-Mediated Rejection. Blood Purif. 2020;49(5):576-585. doi:10.1159/000506504

2019

Mező B, Heilos A, Böhmig GA, et al. Complement Markers in Blood and Urine: No Diagnostic Value in Late Silent Antibody-Mediated Rejection. Transplant Direct. 2019;5(7):e470. Published 2019 Jun 27. doi:10.1097/TXD.0000000000000915

2018

Arnold ML, Kainz A, Hidalgo LG, et al. Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation. Am J Transplant. 2018;18(9):2261-2273. doi:10.1111/ajt.14710

Eskandary F, Regele H, Baumann L, et al. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2018;29(2):591-605. doi:10.1681/ASN.2017070818

Eskandary F, Jilma B, Mühlbacher J, et al. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial. Am J Transplant. 2018;18(4):916-926. doi:10.1111/ajt.14528

2017

Wahrmann M, Mühlbacher J, Marinova L, et al. Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study. Am J Transplant. 2017;17(9):2300-2311. doi:10.1111/ajt.14256